Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia - ScienceDirect
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study | Leukemia
Ibrutinib in B-cell lymphoma: single fighter might be enough? | Cancer Cell International | Full Text
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL | NEJM
Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug | OTT
Ongoing or planned phase 3 trials in the first-line setting for CLL | Download Table
British Journal of Haematology | Wiley Online Library
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial - The Lancet Oncology
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia | NEJM
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia | NEJM
Ibrutinib and Rituximab (IR) is Superior to Chemo-immunotherapy (CIT) in CLL: Big News, or is it really? And did they get it right? - CLL Society
Ibrutinib in the treatment of chronic lymphocytic leukemia: 5 years on - Molica - 2020 - Hematological Oncology - Wiley Online Library
Ibrutinib (PCI-32765) | Btk Inhibitor | MedChemExpress
ALLIANCE - Progression-Free Survival | IMBRUVICA® (ibrutinib) HCP
ALLIANCE A041202 - Study Design | IMBRUVICA® (ibrutinib) HCP
Treatment Initiation and Selection in Newly Diagnosed CLL - ppt download
Management of CLL in 2021 and Beyond - YouTube
1858-Ibrutinib | eviQ
Ibrutinib in Combination with Rituximab or Lenalidomide/Rituximab for Untreated FL | Research To Practice
CHRONIC LYMPHOCYTIC LEUKEMIA
Cancers | Free Full-Text | Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 Study
Tailored Treatment Strategies for Chronic Lymphocytic Leukemia in a Rapidly Changing Era | American Society of Clinical Oncology Educational Book
Ibrutinib combinations in CLL therapy: scientific rationale and clinical results | Blood Cancer Journal
Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia | Annals of Hematology
Cancers | Free Full-Text | First-Line Treatment of Older Patients with CLL: A New Approach in the Chemo-Free Era
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study | Leukemia
